Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibrilLation

NARecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

October 1, 2024

Study Completion Date

May 1, 2025

Conditions
Atrial Fibrillation
Interventions
DEVICE

Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.

Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator

Trial Locations (6)

3435

RECRUITING

St Antonius Ziekenhuis, Nieuwegein

B-9300

RECRUITING

Onze-Lieve-Vrouwziekenhuis (OLV), Aalst

H3G 1A4

RECRUITING

McGill University Health Centre (MUHC), Montreal General Hospital (MGH), Montreal

150 30

RECRUITING

Nemocnice Na Homolce, Prague

A94 E4X7

RECRUITING

Blackrock Health, Dublin

SW17 0QT

RECRUITING

St George'S University Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Adagio Medical

INDUSTRY

NCT05408754 - Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibrilLation | Biotech Hunter | Biotech Hunter